Tags

Type your tag names separated by a space and hit enter

Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Anticancer Res. 2005 May-Jun; 25(3A):1719-23.AR

Abstract

AIMS

(a) To assess the expression patterns of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS.

MATERIALS AND METHODS

Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n=130), and IDC/DCIS (n=36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi2 tests were used to evaluate any statistical differences between different groups. Significance was assumed at p<0.05.

RESULTS

A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p<0.05). Her2/neu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p<0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p<0.05). The Ki67 expression was significantly higher (p<0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression.

CONCLUSION

We demonstrated significantly different expression patterns of Her2/neu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2/neu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor.

Authors+Show Affiliations

Ludwig-Maximilians University Munich, 1st Department of Obstetrics and Gynecology, 80337 Munich, Germany. Ioannis.mylonas@med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16033090

Citation

Mylonas, Ioannis, et al. "Expression of Her2/neu, Steroid Receptors (ER and PR), Ki67 and P53 in Invasive Mammary Ductal Carcinoma Associated With Ductal Carcinoma in Situ (DCIS) Versus Invasive Breast Cancer Alone." Anticancer Research, vol. 25, no. 3A, 2005, pp. 1719-23.
Mylonas I, Makovitzky J, Jeschke U, et al. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anticancer Res. 2005;25(3A):1719-23.
Mylonas, I., Makovitzky, J., Jeschke, U., Briese, V., Friese, K., & Gerber, B. (2005). Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anticancer Research, 25(3A), 1719-23.
Mylonas I, et al. Expression of Her2/neu, Steroid Receptors (ER and PR), Ki67 and P53 in Invasive Mammary Ductal Carcinoma Associated With Ductal Carcinoma in Situ (DCIS) Versus Invasive Breast Cancer Alone. Anticancer Res. 2005 May-Jun;25(3A):1719-23. PubMed PMID: 16033090.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. AU - Mylonas,Ioannis, AU - Makovitzky,Josef, AU - Jeschke,Udo, AU - Briese,Volker, AU - Friese,Klaus, AU - Gerber,Bernd, PY - 2005/7/22/pubmed PY - 2005/9/27/medline PY - 2005/7/22/entrez SP - 1719 EP - 23 JF - Anticancer research JO - Anticancer Res VL - 25 IS - 3A N2 - AIMS: (a) To assess the expression patterns of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS. MATERIALS AND METHODS: Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n=130), and IDC/DCIS (n=36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi2 tests were used to evaluate any statistical differences between different groups. Significance was assumed at p<0.05. RESULTS: A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p<0.05). Her2/neu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p<0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p<0.05). The Ki67 expression was significantly higher (p<0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression. CONCLUSION: We demonstrated significantly different expression patterns of Her2/neu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2/neu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/16033090/Expression_of_Her2/neu_steroid_receptors__ER_and_PR__Ki67_and_p53_in_invasive_mammary_ductal_carcinoma_associated_with_ductal_carcinoma_In_Situ__DCIS__Versus_invasive_breast_cancer_alone_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&amp;pmid=16033090 DB - PRIME DP - Unbound Medicine ER -